CD4 and neoplasm: induced immunogenicity reprogramming of the tumor microenvironment by reducing the microbial load in pancreatic tumors, including a reduction in myeloid-derived suppressor cells (MDSCs) and increased differentiation of M1-type macrophages, and promoted CD4+ T-cell differentiation and CD8+ T-cell activation, thus improving the effect of tumor treatment [32].